02/08/07 4810-73194-01 649179 52288-3

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re application of: Chamberland, et al.

Application No. 10/567,660

Filed: February 8, 2006 Confirmation No. 3960

For: HALOGENATED QUINAZOLINYL

NITROFURANS AS ANTIBACTERIAL

AGENTS

Examiner: Tamthom Ngo Truong

Art Unit: 1624

Attorney Reference No. 4810-73194-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s)_

Date Mailed Fr.

2007

PURSUANT TO 37 C.F.R. § 1.97(d)

COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are two English-language documents and one non-English-language document. Applicants understand that an English-language version of the non-English-language document was provided to the Patent and Trademark Office in an Information Disclosure Statement dated June 20, 2006. Applicants respectfully request that these documents be listed as references cited on the issued patent.

This statement is provided in compliance with 37 C.F.R. § 1.97(e)(1). The undersigned hereby certifies that each item of information contained in this IDS was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the IDS. A copy of that communication, a Search Report dated November 9, 2006, from the European Patent Office, is enclosed. As a result, no fee should be

required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A duplicate copy of this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 595-5300 Facsimile: (503) 595-5301

cc: Docketing

Ву

Travis Young, Ph.D. Registration No. 53,819

FEB 1 2 2007

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4810-73194-01		
Application Number	10/567,660		
Filing Date	February 8, 2006		
First Named Inventor	Chamberland		
Art Unit	1624		
Examiner Name	Tamthom Ngo Truong		

			Examiner Name	Tamthom Ngo Truong
Examiner's Initials*	Cite No. (optional)	Supplementary European Search Report for Application No. EP 04 76 1630, 2 pages, dated November 11, 2006. Moskalenko, N. Yu, et al., "4-Amino—styrylquinazolines – a new class of antiprotozoal drugs," <i>Database Caplus [Online] Chemical Abstracts Service</i> , XP002404560 retrieved from STN, Database accession no. 1987:32975, 2 pages.		
		Khimiko-Farmatsevticheskii Zhurnal, 20(4), 437-446, Coden: KHFZAN; ISSN: 0023-1134, 1986, XPoo2917813. (See cite No. C8 on Information Disclosure Statement dated June 20, 2006.)		
	:	,		

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.